SCHEMBL5134502

SCHEMBL5134502

CCCCn1c(CN(CCc2ccc(C)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
CTSL P07711 1/20 0.41
F2R P25116 2/20 0.41
TP53 P04637 3/20 0.40
POLB P06746 1/20 0.40
HSP90AA1 P07900 2/20 0.38
HSP90AB1 P08238 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136744 0.96 C5AR1 (0.47) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5136702 0.94 C5AR1 (0.51) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5152680 0.94 C5AR1 (0.44) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5136937 0.94 C5AR1 (0.44) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5135741 0.93 C5AR1 (0.48) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5149996 0.92 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5136838 0.92 HTR2A (0.46) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5136695 0.92 C5AR1 (0.43) C5AR1HTR2AHTR2CHTR2BCTSL
SCHEMBL5136897 0.92 C5AR1 (0.55) C5AR1HTR2AHTR2CHTR2BF2R
SCHEMBL5216956 0.92 C5AR1 (0.48) C5AR1HTR2AHTR2CHTR2BCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed